 Endometrial Neoplasms
"Endometrial Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
| Descriptor ID |
D016889
|
| MeSH Number(s) |
C04.588.945.418.948.585 C13.351.500.852.762.200 C13.351.937.418.875.200
|
| Concept/Terms |
Endometrial Neoplasms- Endometrial Neoplasms
- Endometrial Neoplasm
- Neoplasm, Endometrial
- Neoplasms, Endometrial
Endometrial Carcinoma- Endometrial Carcinoma
- Carcinoma, Endometrial
- Carcinomas, Endometrial
- Endometrial Carcinomas
- Endometrial Cancer
- Cancer, Endometrial
- Cancers, Endometrial
- Endometrial Cancers
- Endometrium Cancer
- Cancer, Endometrium
- Cancers, Endometrium
- Cancer of the Endometrium
- Carcinoma of Endometrium
- Endometrium Carcinoma
- Endometrium Carcinomas
- Cancer of Endometrium
- Endometrium Cancers
|
Below are MeSH descriptors whose meaning is more general than "Endometrial Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Endometrial Neoplasms".
This graph shows the total number of publications written about "Endometrial Neoplasms" by people in this website by year, and whether "Endometrial Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 3 | 0 | 3 | | 2002 | 2 | 0 | 2 | | 2004 | 1 | 1 | 2 | | 2005 | 3 | 0 | 3 | | 2006 | 4 | 1 | 5 | | 2007 | 2 | 0 | 2 | | 2008 | 2 | 0 | 2 | | 2009 | 4 | 0 | 4 | | 2010 | 3 | 0 | 3 | | 2011 | 4 | 1 | 5 | | 2012 | 2 | 0 | 2 | | 2013 | 6 | 1 | 7 | | 2014 | 7 | 0 | 7 | | 2015 | 7 | 1 | 8 | | 2016 | 8 | 0 | 8 | | 2017 | 9 | 1 | 10 | | 2018 | 3 | 0 | 3 | | 2019 | 8 | 0 | 8 | | 2020 | 4 | 0 | 4 | | 2021 | 4 | 0 | 4 | | 2022 | 7 | 0 | 7 | | 2023 | 11 | 0 | 11 | | 2024 | 8 | 0 | 8 | | 2025 | 11 | 1 | 12 |
To return to the timeline, click here.
Below are the most recent publications written about "Endometrial Neoplasms" by people in Profiles.
-
Wang SM, Dexter J, Wolsky R, Lefkowits C. Management of Advanced Stage Endometrial Cancer With Non-Measurable Disease After Surgery. Curr Treat Options Oncol. 2025 Sep; 26(9):820-828.
-
Abu-Rustum NR, Campos SM, Amarnath S, Arend R, Barber E, Bradley K, Brooks R, Chino J, Chon HS, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Gaillard S, Giuntoli R, Glaser S, Howitt BE, Landrum L, Lea J, Lee N, Mantia-Smaldone G, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Nieto K, Nwachukwu C, Podoll M, Rodabaugh K, Salani R, Schorge J, Schuetze S, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wyse E, McMillian N, Sambandam V. NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025. J Natl Compr Canc Netw. 2025 Aug; 23(8):284-291.
-
Corr BR, Haggerty A, Gysler SM, Taylor S, Behbakht K, Alldredge J, Lefkowits C, Brubaker LW, Bouts C, Babayan LM, Martin LP, Costello J, Bitler BG, Hu J, Guntupalli SR. A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer. Gynecol Oncol. 2025 Sep; 200:58-67.
-
Lee SS, Secord AA, Friedman S, Hade EM, Smitherman C, Bisht N, Borden L, Jackson AL, Backes F, Thaker P, Arend R, Wright JD, Corr B, Ko E, Konecny G, Podwika S, Bae-Jump V, Hacker KE, Pothuri B. Molecular characteristics by race and ethnicity of patients with high tumor mutational burden, high microsatellite instability, and mismatch repair deficiency: Real-world data from the multi-institutional Endometrial cancer Molecularly Targeted Therapy Consortium (ECMT2). Gynecol Oncol. 2025 Aug; 199:152-158.
-
Gonzalez Bosquet J, Polio A, George E, Tarhini AA, Cosgrove CM, Huang MS, Corr B, Leiser AL, Salhia B, Darcy K, Tarney CM, Dood RL, Dockery LE, Edge SB, Cavnar MJ, Landrum L, Rounbehler RJ, Churchman M, Wagner VM. Training, Validating, and Testing Machine Learning Prediction Models for Endometrial Cancer Recurrence. JCO Precis Oncol. 2025 May; 9:e2400859.
-
Cucinella G, Schivardi G, Zhou XC, AlHilli MM, Wallace S, Covens A, Wohlmuth C, Baiocchi G, Tokgozoglu N, Raspagliesi F, Buda A, Zanagnolo V, Zapardiel I, Jagasia N, Giuntoli R, Glickman A, Peiretti M, Lanner M, Chacon E, Di Guilmi J, Pereira A, Laas E, Fishman A, Nitschmann CC, Kurnit K, Moriarty K, Joehlin-Price A, Lees B, De Brot L, Taskiran C, Bogani G, Landoni F, Chiva L, Grassi T, Bianchi T, Multinu F, De Vitis LA, Hernandez-Gutierrez A, Mastroyannis S, Ghoniem K, Palmieri E, Chiantera V, Maryam S, Fought AJ, McGree ME, Mariani A, Glaser G. Prognostic value of isolated tumor cells in sentinel lymph nodes in intermediate-risk endometrial cancer: results from an international, multi-institutional study. Int J Gynecol Cancer. 2025 Jul; 35(7):101906.
-
Secord AA, Bae-Jump V, Backes F, Thaker P, Gehrig PA, Previs RA, Borden L, Thomas SM, Jackson A, Konecny GE, Duska LR, Arend R, Wright J, Corr B, Maxwell GL, Cosgrove CM, Mullen MM, Washington C, Herzog TJ, Cohen J, Hou J, Gaillard S, Fader AN, Berchuck A, Pothuri B. Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study. Int J Gynecol Cancer. 2025 May; 35(5):101758.
-
Eskander RN, Lee JY, Mirza MR, Lorusso D, MacKay H, Ray-Coquard I, Oaknin A, Gonzalez-Martin A, Hasegawa K, Corr BR, Wu X, Leary A, Hu T, Dutta L, Okpara CE, McKenzie J, Makker V. Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors. Int J Gynecol Cancer. 2025 Sep; 35(9):101812.
-
Corr BR, Erickson BK, Barber EL, Fisher CM, Slomovitz B. Advances in the management of endometrial cancer. BMJ. 2025 Mar 05; 388:e080978.
-
Haight PJ, Sanchez M, Thomas SM, Smitherman C, Cosgrove C, Bae-Jump V, Crafton S, Hacker K, Ko E, Krivak T, Lara O, Moore K, Mullen MM, Pothuri B, Thaker PH, Washington C, Arend R, Corr B, Duska L, Jackson A, Konecny GE, Wright J, Secord A, Backes F. Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study. Gynecol Oncol. 2025 Mar; 194:98-104.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|